Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
Reading miRNAs for Clinical Meaning
Single miRNAs Don’t Say Much, but They May Become Eloquent Biomarkers if We Take Their Testimony in Context
Sorting Out the CRISPR Patent Case
Sounds of Science Podcast
Good Assays for Bad Immunogenicity
Avoid “Bad” Immunogenicity by Using Assays That Are More Sensitive and Can Adapt to Increasingly Complex and Specialized Drugs
FDA: Too Restrictive?
In a debate held on May 8, 2013, major thinkers argued over whether or not the FDA is failing its mandate of protecting the public health, as its approval processes can slow the process of bringing new treatments to market. The debate featured a poll asking participants if they agree with the statement “The FDA’s caution is hazardous to our health.” The results: before the debate, 24% were in favor of that statement, 32% were against it, and 44% were undecided; after the debate, 53% were in favor, 38% were against it, and 9% were undecided. Now, we’re asking GEN readers a similar question.